Market-Moving News for July 25th
$EW
$MXL
$POAI
Industrial Specialties
Health Care
Semiconductors
Technology
Get the next $EW alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/9/2026 | $97.00 | Hold → Buy | TD Cowen | |
| 12/18/2025 | $100.00 | Neutral → Overweight | Analyst | |
| 11/3/2025 | $96.00 | Mkt Perform → Outperform | Raymond James | |
| 10/29/2025 | Underperform → Peer Perform | Wolfe Research | ||
| 10/29/2025 | $98.00 | Hold → Buy | Jefferies | |
| 10/8/2025 | Outperform → Perform | Oppenheimer | ||
| 10/7/2025 | $88.00 | In-line → Outperform | Evercore ISI | |
| 7/29/2025 | $100.00 | Neutral → Buy | BTIG Research |
4 - MAXLINEAR, INC (0001288469) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
TD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00
Analyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00
Raymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
SCHEDULE 13G - MAXLINEAR, INC (0001288469) (Subject)
SCHEDULE 13G/A - MAXLINEAR, INC (0001288469) (Subject)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an
Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholder
Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an
Thursday, Jan. 29, 2026 at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time MaxLinear, Inc. (NASDAQ:MXL), a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated circuits, announced today that it will release its financial results for the fourth quarter 2025 after the close of market on Thursday, Jan. 29, 2026. The company will host a corresponding conference call at 1:30 p.m. Pacific Time, 4:30 p.m. Eastern Time. Conference Call Details Date: Jan. 29, 2026 Time: 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Hosts: Kishore Seendripu, Ph.D., Chief Executive Officer and Steve Litchfield, Chief Financial Officer a
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - MAXLINEAR, INC (0001288469) (Subject)
SC 13G/A - MAXLINEAR, INC (0001288469) (Subject)